A Phase 1 interventional study of Tranexamic acid in Surgery and Postoperative Blood Loss, sponsored by Vanderbilt University Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-07.
Sponsored by Vanderbilt University Medical Center · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing Tranexamic Acid in Postoperative Hemorrhage — 5 open to participants now, 5 under way, 1 of them phase 3. Tranexamic Acid · Postoperative Hemorrhage.
Among the 25 studies testing Tranexamic Acid in Postoperative Hemorrhage, this one is the 22nd largest by planned enrollment, is one of 2 that started in 2023, is the only one in phase 1, and was the 18th registered.
135 studies on the registry are indexed under Postoperative Hemorrhage; 31 are open to participants now.
Browse Postoperative Hemorrhage studies →5 of the 25 studies testing Tranexamic Acid in Postoperative Hemorrhage are open now, in 4 countries. Recruiting first, the newest first:
St. Mary's Research Center, Canada · Sites in Canada
Ages 18+ · Healthy volunteers
Ascension Health · Sites in United States
Ages 18+ · Healthy volunteers
Clinique Saint-Luc · Sites in Belgium
Ages 18+
Ramathibodi Hospital · Sites in Thailand
Ages 18–50
By country, each count listing its studies:
Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →
Of the 17 Postoperative Hemorrhage studies recruiting now, 11 (65%) set no upper age limit and 4 (24%) stop at 75 or younger; 2 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 5 · Phase 4 10
First in 2008; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 100 across 102 interventional studies indexed under Postoperative Hemorrhage.
Median enrollment 116 across the 25 interventional studies. Of the 16 that completed or were terminated, 2 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 25 have an industry lead sponsor. The 10 most frequent:
Vanderbilt University Medical Center is the lead sponsor of 837 studies on the registry; 157 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 92 (73%) have results posted.
Vanderbilt University Medical Center has 2 studies filed under Postoperative Hemorrhage — fewer than ten, so there is no comparison to draw.
1 of the studies testing Tranexamic Acid in Postoperative Hemorrhage that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06208267St. Mary's Research Center, CanadaTranexamic Acid Use on Pain, Mobility and Bleeding Following Total Hip and Total Knee Arthroplasty | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 25 studies testing Tranexamic Acid in Postoperative Hemorrhage, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will be a prospective randomized study to evaluate the effect of tranexamic acid (TXA) use on intraoperative and postoperative outcomes among patients undergoing rhinoplasty by two Facial Plastic surgeons at Vanderbilt. Outcomes will include intra- and post-operative bleeding and postoperative bruising and swelling.
TXA is an antifibrinolytic agent that acts to decrease bleeding by stabilizing the fibrin matrix involved in the clotting cascade. The use of TXA, oral or intravenous, has been extensively used and described in the literature to prevent exsanguination in trauma and in various surgical procedures, as well as for heavy menstrual bleeding. It has been used in the perioperative period during various nasal and sinus surgery, and current research in rhinoplasty suggests that its use may decrease intraoperative bleeding and postoperative eye swelling and bruising.
Currently, IV TXA is used at this institution in some cases by some surgeons in the perioperative period in rhinoplasty surgery, though its used is not standardized and has not been studied. This study will randomize patients undergoing rhinoplasty, with consent, to receive TXA or placebo in the perioperative period. The investigators anticipate collecting 60-100 patients. Outcomes will include intraoperative bleeding, postoperative swelling and bruising (both subjective and based on blinded reviewer analysis of postoperative photographs).
TXA has been used in the perioperative period during various nasal and sinus surgery, and current research in rhinoplasty suggests that its use may decrease intraoperative bleeding and postoperative eye swelling and bruising. In these studies, TXA has been given in intravenous and/or oral form in 1-3 doses in the perioperative period, and there have been no serious adverse effects reported. IV TXA is also FDA approved for use at time of tooth extraction to decrease bleeding, and PO TXA is approved use during the menstrual cycle to decrease heavy menstrual bleeding. There are countless studies in the literature supporting use of both IV and PO TXA in trauma, orthopedic and spine surgery and neurosurgery, and it is widely used in clinical practice in these disciplines. It's use in rhinoplasty is growing, yet has not been studied in larger groups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive 1 gram IV tranexamic acid in the operating room prior to surgical incision.
Drug: Tranexamic acid
Routine care, no tranexamic acid given.
1 gram IV (intravenous) tranexamic acid administered in the operating room just prior to starting the case (10 minutes), at time that routine preoperative antibiotic is given.
Also known as: TXA
Intraoperative bleeding as measured by the weight of surgical sponges used
Weight of surgical sponges used (grams)
Time frame: During surgery
Intraoperative bleeding as measured by the volume of blood in suction canister
Volume of blood in suction canister (Milliliters)
Time frame: Intraoperative
Postoperative bleeding as measured by patient-rated bleeding on Visual Analog Scale (VAS)
A single patient-answered question visual analog scale (VAS) used to measure the amount of post-operative bleeding from the nose the participant experienced (1 to 5 scale with 5 being the most)
Time frame: Up to one week following surgery.
Postoperative edema
Swelling around the eyes (Visual Analog Scale, 1 to 5 scale with 5 being the most)
Time frame: Up to one week following surgery
Postoperative ecchymosis
Bruising around the eyes (Visual Analog Scale, 1 to 5 scale with 5 being the most)
Time frame: Up to one week following surgery
Postoperative bleeding as measured by the number of medical interventions needed to control bleeding
Number of interventions required to control bleeding (surgical or procedural interventions)
Time frame: Up to one week following surgery
Plan to share: No — No plan at this time to share.
Started Apr 2023 (actual). Primary completion is estimated for Apr 2029, 72 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tranexamic Acid
Vanderbilt University Medical Center →